Clinical Trial Detail

NCT ID NCT03070392
Title Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Immunocore Ltd
Indications

uveal melanoma

Therapies

Dacarbazine

Ipilimumab

Pembrolizumab

Tebentafusp

Age Groups: adult senior

No variant requirements are available.